摘要
目的探讨参苓白术颗粒联合西药对小儿秋季腹泻患儿血清超敏C反应蛋白(hs-CRP)及总病程的影响。方法将60例小儿秋季腹泻患儿按随机数字表法分为观察组和对照组,各30例,均给予常规西药治疗,合理喂养,观察组患儿在此基础上加用参苓白术颗粒治疗。比较两组患儿的临床疗效、hs-CRP水平及症状恢复时间与总病程。结果观察组患儿总有效率为90.00%,显著高于对照组的66.67%(P<0.05);治疗后,两组患儿的hs-CRP水平均显著降低(P<0.01),观察组为(3.65±1.48)ng/L,显著低于对照组的(6.22±2.50)ng/L(P<0.01);观察组患儿大便次数恢复正常时间为(3.45±1.00)d,大便性状恢复正常时间为(4.22±1.23)d,总病程为(6.49±1.07)d,分别显著低于对照组的(5.14±1.20)d,(6.00±1.36)d,(9.26±2.05)d(P<0.01)。结论参苓白术颗粒联合西药治疗小儿秋季腹泻临床疗效显著,可显著降低患儿血清hs-CRP水平,缩短症状恢复时间与总病程,尽快促进患儿康复。
Objective To explore the effect of Shenling Baizhu Granules combined with western medicine on serum hs- CRP and total course of disease of children with autumn diarrhea. Methods 60 cases of children with autumn diarrhea were randomized into the observation group and the control group,30 cases in each group. Both groups were treated with routine western medicine and reasonable feeding. The observation group was additionally treated with Shenling Baizhu Granules. The clinical efficacy,hs- CRP levels,symptom recovery time and total course of disease were compared between the two groups. Results The total effective rate in the observation group was 90. 00%,which was significantly higher than 66. 67% in the control group（ P〈0. 05）; after treatment,the hs- CRP levels in the two groups decreased significantly（ P〈0. 01）,and the observation group was（ 3. 65 ± 1. 48） ng / L,which was obviously lower than（ 6. 22 ± 2. 50） ng / L in the control group（ P〈0. 01）; the time of stool frequency recovery was（ 3. 45 ± 1. 00） d,the time of stool character recovery was（ 4. 22 ± 1. 23） d and the total course of disease was（ 6. 49 ± 1. 07） d in the observation group,which were significantly shorter than（ 5. 14 ± 1. 20） d,（ 6. 00 ± 1. 36） d,（ 9. 26 ± 2. 05） d in the control group（ P〈0. 01）. Conclusion The clinical efficacy of Shenling Baizhu Granules combined with western medicine in the treatment of children with autumn diarrhea is remarkable,which can significantly reduce the serum hs- CRP level,shorten the symptom recovery time and total course of disease and promote the recovery of children as soon as possible.
出处
《中国药业》
CAS
2016年第14期53-55,共3页
China Pharmaceuticals
